The team conducts research evaluating current approaches to screening and investigating potential new screening technologies.
We study how to optimise the efficacy and cost-effectiveness, and minimise the harms of screening programmes. We research technologies to improve existing screening programmes; and others for cancer sites for which no tests yet exist.
We evaluate current approaches to screening and study new screening technologies.
We aim to identify how to optimise the efficacy and cost-effectiveness, and minimise the harms of screening programmes. Specifically we generate evidence on screening intervals, the benefits and harms of screening at different ages, and reasons for differences in screening performance. Additionally, we research risk-based screening and the potential for personalised screening regimens. Varying screening intervals and technologies based on individual risk has the potential to deliver greater support to those at greater risk and minimise screening harms to those at lower risk. We have a track record of research that has changed cancer screening guidelines and policy.
We study technologies with the potential to improve existing screening programmes and others with the objective of developing screening at new sites. For instance, we are studying vaginal self-sampling which may improve cervical screening coverage. And, together with Professor Fitzgerald’s group in Cambridge, we are studying the potential of a Cytosponge to screen for Barrett’s oesophagus and to reduce mortality from adenocarcinoma of the oesophagus. We will assess polygenic risk with the goal of developing risk-based personalised screening intervals for breast and prostate cancer.
Main ongoing projects include:
- Barrett's oEsophagus STudy 2 (BEST2)
- Breast and Bowel Cancer Screening
- Cervical screening and HPV control
- Cervical screening audit
- Comparison of cancer screening participation in the UK and US
- European randomised trial of screening for prostate cancer
- Evaluation of HPV primary Screening Pilot
- Evaluation of pilot of immunochemical test for bowel screening
- Faecal immunochemical testing (FIT) for adenoma surveillance
- Long term follow up of RCT of annual mammographic screening from age 40
- Mammographic screening breast density
- Natural history estimation for screening evaluation and planning
- Policy Research Unit on cancer awareness, screening and early diagnosis
- Risk of preterm delivery after excision of the cervical transformation zone
- Study of PSA testing in primary care in England
- The validation of interim utcome measures for the evaluation of interventions promoting increased cancer awareness and early detection
A full list with details can be found under Research Projects.
- Dr Alejandra Castanon - Epidemiologist
- Amanda Dibden - Statistician
- Professor Stephen Duffy - Professor of Cancer Screening
- Raissa Frank - Senior Data Manager
- Matthew Gillman - Computational Statistician
- Ashan Green - Senior Data Manager
- Dr Jean-Pierre Laake - Epidemiologist
- Dr Rebecca Landy - Statistician
- Dr Anita Lim - Senior Epidemiologist
- Roberta Maroni - Statistician
- Dr Nathalie Massat - Senior Statistician
- Christopher Mathews - Senior Data Manager
- Dr Jonathan Myles - Senior Data Manager
- Dr Judith Offman - Epidemiologist
- Dharmishta Parmar - Senior Data Manager
- Dr Francesca Pesola - Statistician
- Polly Rawlinson - Senior Administrator
- Dr Matejka Rebolj - Senior Epidemiologist
- Professor Peter Sasieni - Professor of Biostatistics and Cancer Epidemiology
- Shama Sheihk - Statistician
- Daniel Vulkan - Statistician
- Emma Wang - PhD Student